Page last updated: 2024-08-21

quinazolines and akt-i-1,2 compound

quinazolines has been researched along with akt-i-1,2 compound in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baselga, J; Chandarlapaty, S; Grbovic-Huezo, O; Majumder, PK; Rodrik-Outmezguine, V; Rosen, N; Sawai, A; Scaltriti, M; Serra, V	1
Bertrand, M; Correa, RJ; DiMattia, GE; Fazio, EN; McGee, J; Peart, TM; Préfontaine, M; Shepherd, TG; Sugimoto, A; Valdes, YR	1

Other Studies

2 other study(ies) available for quinazolines and akt-i-1,2 compound

Article	Year
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell, 2011, Jan-18, Volume: 19, Issue:1 Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays	2011
Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability. Carcinogenesis, 2014, Volume: 35, Issue:9 Topics: Allosteric Regulation; Antineoplastic Agents; Ascites; Autophagy; Benzylamines; Cell Line, Tumor; Cell Survival; Chloroquine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Spheroids, Cellular	2014

Article

Year

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

Cancer cell, 2011, Jan-18, Volume: 19, Issue:1

Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays

2011

Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.

Carcinogenesis, 2014, Volume: 35, Issue:9

Topics: Allosteric Regulation; Antineoplastic Agents; Ascites; Autophagy; Benzylamines; Cell Line, Tumor; Cell Survival; Chloroquine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Inhibitory Concentration 50; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Spheroids, Cellular

2014